Drug intelligence / Profile preview

erlotinib + hydroxychloroquine

Development stage: Unknown
Lead developer: Astellas Pharma
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and hydroxychloroquine, an anti-autophagy agent. This combination has been studied primarily in patients with advanced non-small cell lung cancer (NSCLC), particularly those with EGFR mutations who previously benefited from EGFR tyrosine kinase inhibitor therapy. The rationale behind this combination is that hydroxychloroquine may inhibit autophagy, a potential resistance mechanism to erlotinib.

Other names: HCQ + erlotinibHydroxychloroquine and Erlotinib

Targets

Autophagy (Autophagy machinery (ATG family))EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on erlotinib + hydroxychloroquine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on erlotinib + hydroxychloroquine.

Explore the full profile